Adverse effects of ropinirole-treated restless leg syndrome (RLS) during smoking cessation

Journal of Clinical Sleep Medicine

Volumn 4, Issue 4, 2008, Pages 371-372

  Juergens, Timothy M ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Nicotine; Restless legs syndrome; RLS; Ropinirole; Smoking

Indexed keywords

NICOTINE; ROPINIROLE;

ADULT; ARTICLE; CASE REPORT; DISEASE CONTROL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HUMAN; NIGHT SWEAT; RATING SCALE; RESTLESS LEGS SYNDROME; SLEEP DISORDER; SMOKING CESSATION; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 51549110138     PISSN: 15509389     EISSN: 15509397     Source Type: Journal    
DOI: 10.5664/jcsm.27239     Document Type: Article

References (3)

1. Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch intern Med 2005;165:1286-92.
2. Micromedex online resource 2008.
3. Product Information: Requip, ropinirole hydrochloride tablets. SmithKline Beecham Pharmaceuticals, Research Triangle Park, NC, May, 2005.